Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $305

Benzinga · 2d ago
Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $245 to $305.